Exemplis Discimus 2011, 155(1):3-9

Aliquam nulla tellus, fringilla non, tristique vitae, porttitor vitae, ante.

Sakura Qui Madinea, Ares Sileroa, Jarvis Wana, Surro Renza, Jhoren Pahleea, Avin Parkereb
a Institute of Thoracic surgery, Ord Mantell Faculty Hospital, Endor Republic
b Laboratory of Rheumatology, University Hospital of Brak, Republic of Felucia

Background: Phasellus ut lorem vel dolor auctor porttitor. Aenean a ipsum tincidunt mi rhoncus pellentesque. Cras justo nisl, gravida eu, posuere et, mattis quis, tellus. Proin turpis nibh, rhoncus ac, placerat a, ultrices quis, erat.. Vestibulum enim est, pulvinar euismod, viverra non, sollicitudin a, nisi. In dui eros, consectetuer vitae, consectetuer eget, hendrerit quis, massa. Vestibulum metus tellus, porttitor eu, placerat et, ullamcorper eget, nunc. Lorem ipsum dolor sit amet, consectetuer adipiscing elit.

Methods: Vestibulum ante ipsum primis in faucibus orci luctus et ultrices posuere cubilia Curae; Proin dictum, eros at fringilla imperdiet, metus eros hendrerit nisl, at suscipit massa turpis non mi. Nulla pharetra, erat eget tempor mollis, augue libero varius urna, at porttitor felis quam et nibh.

Conclusions: Cras justo nisl, gravida eu, posuere et, mattis quis, tellus. Sed id tortor faucibus tortor mollis sagittis. Pellentesque sem diam, varius a, vehicula eu, lacinia ut, augue. Nullam orci leo, porttitor non, rhoncus nec, congue porttitor, magna. Duis sit amet nisl at felis convallis dictum. Duis lorem mi, consectetuer vel, consectetuer nec, suscipit quis, augue. Donec sed diam tincidunt augue tempus adipiscing. Phasellus tellus sem, cursus eu, vulputate non, malesuada eu, arcu.

Keywords: Proin vitae diam, Sed nec nisl, Curabitur ut sem

Received: September 9, 2010; Accepted: December 13, 2010; Published: March 1, 2011 

Open full article

References

  1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96. Go to original source... Go to PubMed...
  2. Merrill RM, Stephenson RA. Trends in mortality rates in patients with prostate cancer during the era of prostate specific antigen screening. J Urol 2000;163:503-10. Go to original source... Go to PubMed...
  3. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005;29:1228-42. Go to original source... Go to PubMed...
  4. http://www.svod.cz/
  5. Strope SA, Andriole GL. Update on chemoprevention for prostate cancer. Curr Opin Urol 2010;20:194-7. Go to original source... Go to PubMed...
  6. Dvoracek J. Nadory prostaty. In: Dvoracek J, Babjuk M.: Onkourologie, 1. vydani, Galen; 2005;225-242.
  7. Klein EA, Platz EA, Thompson IM. Epidemiology, Etiology, and Prevention of Prostate Cancer. In: Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA. Campbell-Walsh Urology, Saunders, Philadelphia, 9th ed., 2007;2854-2867.
  8. Carter BS, Beaty TH, Steinberg GD, Childs B, Walsh PC. Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci U S A 1992;89:3367-71. Go to original source... Go to PubMed...
  9. Bratt O. Hereditary prostate cancer: clinical aspects. J Urol 2002;168:906-13. Go to original source... Go to PubMed...
  10. Carter BS, Bova GS, Beaty TH, Steinberg GD, Childs B, Isaacs WB, Walsh PC. Hereditary prostate cancer: epidemiologic and clinical features. J Urol 1993;150:797-802. Go to PubMed...
  11. Schaid DJ, McDonnell SK, Blute ML, Thibodeau SN. Evidence for autosomal dominant inheritance of prostate cancer. Am J Hum Genet 1998;62:1425-38. Go to original source... Go to PubMed...
  12. Zeegers MP, Jellema A, Ostrer H. Empiric risk of prostate carcinoma for relatives of patients with prostate carcinoma: a metaanalysis. Cancer 2003;97:1894-903. Go to original source... Go to PubMed...
  13. Bruner DW, Moore D, Parlanti A, Dorgan J, Engstrom P. Relative risk of prostate cancer for men with affected relatives: systematic review and meta-analysis. Int J Cancer 2003;107:797-803. Go to original source... Go to PubMed...
  14. Kalish LA, McDougal WS, McKinlay JB. Family history and the risk of prostate cancer. Urology 2000;56:803-6. Go to original source... Go to PubMed...
  15. Mastalski K, Coups EJ, Ruth K, Raysor S, Giri VN. Substantial family history of prostate cancer in black men recruited for prostate cancer screening: results from the Prostate Cancer Risk Assessment Program. Cancer 2008;113:2559-64. Go to original source... Go to PubMed...
  16. Chen YC, Page JH, Chen R, Giovannucci E. Family history of prostate and breast cancer and the risk of prostate cancer in the PSA era. Prostate 2008;68:1582-91. Go to original source... Go to PubMed...
  17. Valeri A, Briollais L, Azzouzi R, Fournier G, Mangin P, Berthon P, Cussenot O, Demenais F. Segregation analysis of prostate cancer in France: evidence for autosomal dominant inheritance and residual brother-brother dependence. Ann Hum Genet 2003;67:125-37. Go to original source... Go to PubMed...
  18. Verhage BA, Baffoe-Bonnie AB, Baglietto L, Smith DS, Bailey- Wilson JE, Beaty TH, Catalona WJ, Kiemeney LA. Autosomal dominant inheritance of prostate cancer: a confirmatory study. Urology 2001;57:97-101. Go to original source... Go to PubMed...
  19. Page WF, Braun MM, Partin AW, Caporaso N, Walsh P. Heredity and prostate cancer: a study of World War II veteran twins. Prostate 1997;33:240-5. Go to original source... Go to PubMed...
  20. Gronberg H, Damber L, Damber JE. Studies of genetic factors in prostate cancer in a twin population. J Urol 1994;152:1484-7. Go to PubMed...
  21. Kupelian PA, Kupelian VA, Witte JS, Macklis R, Klein EA. Family history of prostate cancer in patients with localized prostate cancer: an independent predictor of treatment outcome. J Clin Oncol 1997;15:1478-80. Go to PubMed...
  22. Bova GS, Partin AW, Isaacs SD, Carter BS, Beaty TL, Isaacs WB, Walsh PC. Biological aggressiveness of hereditary prostate cancer: long-term evaluation following radical prostatectomy. J Urol 1998;160:660-3. Go to original source... Go to PubMed...
  23. Gronberg H, Damber L, Tavelin B, Damber JE. No difference in survival between sporadic, familial and hereditary prostate cancer. Br J Urol 1998;82:564-7. Go to original source... Go to PubMed...
  24. Hanlon AL, Hanks GE. Patterns of inheritance and outcome in patients treated with external beam radiation for prostate cancer. Urology 1998;52:735-8. Go to original source... Go to PubMed...
  25. Herkommer K, Paiss T, Merz M, Gschwend JE, Kron M. Association of a positive family history with histopathology and clinical course in early-onset prostate cancer. Urologe A 2006;45:1532-9. Go to original source... Go to PubMed...
  26. Roupret M, Fromont G, Bitker MO, Gattegno B, Vallancien G, Cussenot O. Outcome after radical prostatectomy in young men with or without a family history of prostate cancer. Urology 2006;67:1028-32. Go to original source... Go to PubMed...
  27. Robbins AS, Yin D, Parikh-Patel A. Differences in prognostic factors and survival among White men and Black men with prostate cancer, California, 1995-2004. Am J Epidemiol. 2007;166:71-8. Go to original source... Go to PubMed...
  28. Gottlieb B, Beitel LK, Wu JH, Trifiro M. The androgen receptor gene mutations database (ARDB): 2004 update. Hum Mutat 2004;23:527-33. Go to original source... Go to PubMed...
  29. Brooke GN, Bevan CL. The role of androgen receptor mutations in prostate cancer progression. Curr Genomics 2009;10:18-25. Go to original source... Go to PubMed...
  30. Lukes M: Hereditarni karcinom prostaty. In: Zalesky M, Lukes M: Molekularni genetika karcinomu prostaty. Galen, 2002;77-89.
  31. Narla G, Friedman SL, Martignetti JA. Kruppel cripples prostate cancer: KLF6 progress and prospects. Am J Pathol 2003;162:1047- 52. Go to original source... Go to PubMed...
  32. Suzuki H, Ueda T, Ichikawa T, Ito H. Androgen receptor involvement in the progression of prostate cancer. Endocr Relat Cancer 2003;10:209-16. Go to original source... Go to PubMed...
  33. Chen C, Lamharzi N, Weiss NS, Etzioni R, Dightman DA, Barnett M et al. Androgen receptor polymorphisms and the incidence of prostate cancer. Cancer Epidemiol Biomarkers Prev 2002;11:1033- 40. Go to PubMed...
  34. Silva Neto B, Koff WJ, Biolchi V et al. Polymorphic CAG and GGC repeat lengths in the androgen receptor gene and prostate cancer risk: analysis of a Brazilian population. Cancer Invest 2008;26:74-80. Go to original source... Go to PubMed...
  35. Brinkmann AO. Molecular basis of androgen insensitivity. Mol Cell Endocrinol 2001;179:105-9. Go to original source... Go to PubMed...
  36. Marcelli M, Ittmann M, Mariani S, Sutherland R, Nigam R, Murthy L, Zhao Y, DiConcini D, Puxeddu E, Esen A, Eastham J, Weigel NL, Lamb DJ. Androgen receptor mutations in prostate cancer. Cancer Res 2000;60:944-9. Go to PubMed...
  37. Ntais C, Polycarpou A, Ioannidis JP. SRD5A2 gene polymorphisms and the risk of prostate cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2003;12:618-24. Go to PubMed...
  38. Cunningham JM, Hebbring SJ, McDonnell SK, Cicek MS, Christensen GB, Wang L, Jacobsen SJ, Cerhan JR, Blute ML, Schaid DJ, Thibodeau SN. Evaluation of genetic variations in the androgen and estrogen metabolic pathways as risk factors for sporadic and familial prostate cancer. Cancer Epidemiol Biomarkers Prev 2007;16:969-78. Go to original source... Go to PubMed...
  39. Ostrander EA, Johannesson B. Prostate cancer susceptibility loci: finding the genes. Adv Exp Med Biol 2008;617:179-90. Go to original source... Go to PubMed...
  40. Stanford JL, McDonnell SK, Friedrichsen DM, Carlson EE, Kolb S, Deutsch K et al. Prostate cancer and genetic susceptibility: a genome scan incorporating disease aggressiveness. Prostate 2006;66:317-25. Go to original source... Go to PubMed...
  41. Easton DF, Schaid DJ, Whittemore AS, Isaacs WJ. Where are the prostate cancer genes? A summary of eight genome wide searches. Prostate 2003;57:261-9. Go to original source... Go to PubMed...
  42. Schaid DJ. The complex genetic epidemiology of prostate cancer. Hum Mol Genet 2004;13 Spec No 1:R103-21. Go to original source... Go to PubMed...
  43. Hatcher D, Daniels G, Osman I, Lee P. Molecular mechanisms involving prostate cancer racial disparity. Am J Transl Res 2009;1:235-48. Go to PubMed...
  44. Simard J, Dumont M, Labuda D, Sinnett D, Meloche C, El-Alfy M, Berger L, Lees E, Labrie F, Tavtigian SV. D et al. Prostate cancer susceptibility genes: lessons learned and challenges posed. Endocr Relat Cancer 2003;10:225-59. Go to original source... Go to PubMed...
  45. http://www.ncbi.nlm.nih.gov/entrez/ (OMIM Online Mendelian Inheritance in Men)
  46. Klein EA: Geneticka nachylnost a oxidacni stres u karcinomu prostaty: integrovany model s doporucenimi pro prevenci. Urol List 2006;4(4),19-24.
  47. Smith JR, Freije D, Carpten JD, Grönberg H, Xu J, Isaacs SD, Brownstein MJ, Bova GS, Guo H, Bujnovszky P, Nusskern DR, Damber JE, Bergh A, Emanuelsson M, Kallioniemi OP, Walker- Daniels J, Bailey-Wilson JE, Beaty TH, Meyers DA, Walsh PC, Collins FS, Trent JM, Isaacs WB. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 1996;274:1371-4. Go to original source... Go to PubMed...
  48. Grönberg H, Isaacs SD, Smith JR, Carpten JD, Bova GS, Freije D, Xu J, Meyers DA, Collins FS, Trent JM, Walsh PC, Isaacs WB. Characteristics of prostate cancer in families potentially linked to the hereditary prostate cancer 1 (HPC1) locus. JAMA 1997;278:1251-5. Go to original source... Go to PubMed...
  49. Li H, Tai BC. RNASEL gene polymorphisms and the risk of prostate cancer: a meta-analysis. Clin Cancer Res 2006;12:5713-9. Go to original source... Go to PubMed...
  50. Shook SJ, Beuten J, Torkko KC, Johnson-Pais TL, Troyer DA, Thompson IM, Leach RJ. KC et al. Association of RNASEL variants with prostate cancer risk in Hispanic Caucasians and African Americans. Clin Cancer Res 2007;13:5959-64. Go to original source... Go to PubMed...
  51. Rennert H, Bercovich D, Hubert A, Abeliovich D, Rozovsky U, Bar-Shira A, Soloviov S, Schreiber L, Matzkin H, Rennert G, Kadouri L, Peretz T, Yaron Y, Orr-Urtreger A. A novel founder mutation in the RNASEL gene, 471delAAAG, is associated with prostate cancer in Ashkenazi Jews. Am J Hum Genet 2002;71:981- 4. Go to original source... Go to PubMed...
  52. Orr-Urtreger A, Bar-Shira A, Bercovich D, Matarasso N, Rozovsky U, Rosner S, Soloviov S, Rennert G, Kadouri L, Hubert A, Rennert H, Matzkin H. RNASEL mutation screening and association study in Ashkenazi and non-Ashkenazi prostate cancer patients. Cancer Epidemiol Biomarkers Prev 2006;15:474-9. Go to original source... Go to PubMed...
  53. Schlaberg R, Choe DJ, Brown KR, Thaker HM, Singh IR. XMRV is present in malignant prostatic epithelium and is associated with prostate cancer, especially high-grade tumors. Proc Natl Acad Sci USA 2009;106:16351-6. Go to original source... Go to PubMed...
  54. Rebbeck TR, Walker AH, Zeigler-Johnson C, Weisburg S, Martin AM, Nathanson KL, Wein AJ, Malkowicz SB. Association of HPC2/ELAC2 genotypes and prostate cancer. Am J Hum Genet 2000;67:1014-9. Go to original source... Go to PubMed...
  55. Shea PR, Ferrell RE, Patrick AL, Kuller LH, Bunker CH. ELAC2 and prostate cancer risk in Afro-Caribbeans of Tobago. Hum Genet 2002;111:398-400. Go to original source... Go to PubMed...
  56. Kouprina N, Pavlicek A, Noskov VN, Solomon G, Otstot J, Isaacs W, Carpten JD, Trent JM, Schleutker J, Barrett JC, Jurka J, Larionov V. Dynamic structure of the SPANX gene cluster mapped to the prostate cancer susceptibility locus HPCX at Xq27. Genome Res 2005;15:1477-86. Go to original source... Go to PubMed...
  57. Baffoe-Bonnie AB, Smith JR, Stephan DA, Schleutker J, Carpten JD, Kainu T, Gillanders EM, Matikainen M, Teslovich TM, Tammela T, Sood R, Balshem AM, Scarborough SD, Xu J, Isaacs WB, Trent JM, Kallioniemi OP, Bailey-Wilson JE. A major locus for hereditary prostate cancer in Finland: localization by linkage disequilibrium of a haplotype in the HPCX region. Hum Genet 2005;117:307-16. Go to original source... Go to PubMed...
  58. Farnham JM, Camp NJ, Swensen J, Tavtigian SV, Albright LA. Confirmation of the HPCX prostate cancer predisposition locus in large Utah prostate cancer pedigrees. Hum Genet 2005;116:179-85. Go to original source... Go to PubMed...
  59. Berry R, Schroeder JJ, French AJ, McDonnell SK, Peterson BJ, Cunningham JM, Thibodeau SN, Schaid DJ. Evidence for a prostate cancer-susceptibility locus on chromosome 20. Am J Hum Genet 2000;67:82-91. Go to original source... Go to PubMed...
  60. Sun J, Hsu FC, Turner AR, Zheng SL, Chang BL, Liu W, Isaacs WB, Xu J. Meta-analysis of association of rare mutations and common sequence variants in the MSR1 gene and prostate cancer risk. Prostate 2006;66:728-37. Go to original source... Go to PubMed...
  61. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310:644-8. Go to original source... Go to PubMed...
  62. Jamaspishvili T, Kral M, Khomeriki I, Student V, Kolar Z, Bouchal J. Urine markers in monitoring for prostate cancer. Prostate Cancer Prostatic Dis 2010;13:12-9. Go to original source... Go to PubMed...
  63. Albadine R, Latour M, Toubaji A, Haffner M, Isaacs WB, A Platz E, Meeker AK, Demarzo AM, Epstein JI, Netto GJ. TMPRSS2- ERG gene fusion status in minute (minimal) prostatic adenocarcinoma. Mod Pathol 2009;22:1415-22. Go to original source... Go to PubMed...
  64. Koivisto PA, Hyytinen ER, Matikainen M, Tammela TL, Ikonen T, Schleutker J. Kruppel-like factor 6 germ-line mutations are infrequent in Finnish hereditary prostate cancer. J Urol 2004;172:506-7. Go to original source... Go to PubMed...
  65. Dong JT. Prevalent mutations in prostate cancer. J Cell Biochem 2006;97:433-47. Go to original source... Go to PubMed...

Return to the content